Evaluation of drug resistance in pulmonary tuberculosis patients at Sureyyapasa Chest Diseases Hospital, Istanbul, Turkey

• Published in: The international journal of tuberculosis and lung disease Vol. 12; no. 6; pp. 631 - 635
• Main Authors: KARAGOZ, T, PAZARLI, P, MOCIN, O. Y, DUMAN, D, DUMAN, G, SALTURK, C, UNAL, O
• Format: Journal Article
• Language: English
• Published: Paris, France IUATLD 01.06.2008; Union internationale contre la tuberculose et les maladies respiratoires
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular - therapeutic use; Bacterial diseases; Bacterial diseases of the respiratory system; Biological and medical sciences; Drug Resistance; Human bacterial diseases; Humans; Infectious diseases; Male; Medical sciences; Middle Aged; Miscellaneous; Mycobacterium tuberculosis; Pneumology; Prevention and actions; Public health. Hygiene; Public health. Hygiene-occupational medicine; Rifampin - therapeutic use; Sputum - microbiology; Surveillance; Tuberculosis; Tuberculosis, Multidrug-Resistant - epidemiology; Tuberculosis, Pulmonary - drug therapy; Tuberculosis, Pulmonary - epidemiology; Turkey - epidemiology; Asia; Turkey; Human; Lung disease; Evaluation; Treatment resistance; Respiratory disease; Pulmonary tuberculosis; tuberculosis; Thorax; Mycobacterial infection; Infection; Surveillance; Bacteriosis; Tropical medicine; Antituberculous agent; drug resistance; Pneumology
• ISSN: 1027-3719; 1815-7920

SETTING: Sureyyapasa Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey.OBJECTIVE: To determine levels of Mycobacterium tuberculosis resistance to first-line drugs in patients with pulmonary tuberculosis (PTB).DESIGN: Between 1 January and 31 December 2005, all hospitalised PTB patients with culture-positive M. tuberculosis specimens and corresponding drug susceptibility tests (DST) for isoniazid (INH), rifampicin (RMP), streptomycin (SM) and ethambutol, routinely performed for every tuberculosis (TB) case at our centre, were included.RESULTS: Of a total of 1513 cases, 1277 (84.4%) were new and 236 (15.6%) were previously treated cases. Of the 1513 isolates, 290 (19%) isolates were resistant to at least one of the drugs tested. Resistance among new and previously treated cases was respectively 16.3% (209 of 1277) and 34.3% (81/236). Any SM resistance and any INH resistance were the most common drug resistance in new cases, while any RMP resistance was the most common drug resistance in previously treated cases. Multidrug resistance was detected in 3.2% (n = 41) of new cases and in 13.5% (n = 32) of previously treated cases.CONCLUSION: Planning for TB control requires an assessment of the number and distribution of drug-resistant cases, with laboratories providing accurate and reliable results.